Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Apr;103(4):e165-e168.
doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5.

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis

Richa Manwani  1 , Darren Foard  1 , Shameem Mahmood  1 , Sajitha Sachchithanantham  1 , Thirusha Lane  1 , Cristina Quarta  1 , Taryn Youngstein  1 , Tamer Rezk  1 , Helen J Lachmann  1 , Julian D Gillmore  1 , Marianna Fontana  1 , Carol Whelan  1 , Philip N Hawkins  1 , Ashutosh Wechalekar  2
Affiliations
Multicenter Study

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis

Richa Manwani et al. Haematologica. 2018 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival of the entire cohort of stage IIIb AL patients, by hematologic response and by treatment. (A) The median overall survival in this group of 179 patients with stage IIIb cardiac immunoglobulin light chain amyloidosis was 6 months. Patients who opted for palliative care and were not treated with chemotherapy (17% of the cohort) are included in this analysis. (B) Median overall survival in those patients who achieved a complete response (CR)/very good partial response (VGPR) or partial response (PR) or did not have a response (NR - including patients who died with or without treatment) was 38 months, 7.4 months and 2.6 months, respectively (log rank P<0.0001). (C) Median overall survival in those patients who had a CR/VGPR at day 30 was 26 months, compared to 5 months in patients who achieved less than a VGPR. (D) There was no significant difference in median overall survival between patients treated with bortezomib-based regimes or CTD.
See this image and copyright information in PMC

References

    1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924–1933. - PMC - PubMed
    1. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757. - PubMed
    1. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–995. - PMC - PubMed
    1. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427. - PubMed
    1. Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168(2):186–206. - PubMed

Substances

LinkOut - more resources